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Renal endothelial damage is pivotal in the initiation and progression of renal disease. Damaged renal endothelium may be
regenerated through proliferation of local endothelium and circulation-derived endothelial progenitor cells. Activation of the
PPAR-γ-receptors present on endothelial cells aﬀects their cellular behavior. Proliferation, apoptosis, migration, and angiogenesis
by endothelial cells are modulated, but may involve both stimulation and inhibition depending on the speciﬁc circumstances.
PPAR-γ-receptor activation stimulates the production of nitric oxide, C-type natriuretic peptide, and superoxide dismutase, while
endothelin-1productionis inhibited.Together, theyaugment endothelial function,resultinginbloodpressurelowering anddirect
renoprotective eﬀects. The presentation of adhesion molecules and release of cytokines recruiting inﬂammatory cells are inhibited
by PPAR-γ-agonism. Finally, PPAR-γ-receptors are also found on endothelial progenitor cells and PPAR-γ-agonists stimulate
progenitor-mediated endothelial repair. Together, the stimulatory eﬀects of PPAR-γ-agonism on endothelium make an important
contribution to the beneﬁcial actions of PPAR-γ-agonists on renal disease.
Copyright © 2008 P. E. Westerweel and M. C. Verhaar. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
PPAR-γ-agonists are widely used for their insulin-sensitizing
actions in the treatment of type 2 diabetes mellitus, but
have additional therapeutic potential beyond the metabolic
eﬀects. Currently, the clinically most used PPAR-γ-agonistic
drugs are the thiazolidinediones (TZDs). PPAR-γ-agonists
may favorably aﬀect the course of renal disease in both
diabetic and nondiabetic conditions [1, 2]. In nondiabetic
animals, beneﬁcial eﬀects have been shown for anti-GBM
antibody-induced crescentic glomerulonephritis [3], passive
Heymann nephritis [4], the development of glomeruloscle-
rosis after 5/6 nephrectomy [5], renal ischemia-reperfusion
induceddamage[6],andanti-Thy-1-glomerulonephritis[7].
One potential mechanism is the modulation of endothe-
lial cell function through activation of PPAR-γ receptors,
which are expressed on glomerular endothelium [8, 9]. In
response to injury, the endothelial expression of PPAR-γ-
receptorsmaybeincreased,forexample,astransientlyoccurs
after ischemia- reperfusion [8, 9]. Treatment with PPAR-γ-
agonistsalsoincreasestheexpressionofPPAR-γ-receptorson
renal endothelium in both the glomerulus and the capillary
endothelium of the medullary vasa recta [10]. The relevance
for renal disease of activating the PPAR-γ-receptors on renal
endothelium is becoming increasingly clear and is the focus
of this review.
2. THE ROLE OF ENDOTHELIUM IN RENAL DISEASE
Renal microvascular endothelial injury is a pivotal
pathogenic factor for various renal diseases. Renal disease
conditions involving prominent endothelial damage include
ischemic nephropathy, glomerulonephritis, interstitial neph-
ritis,andallograftrejection[11,12].Endothelial dysfunction
and attenuated angiogenesis contribute to declining renal
function with ageing [13] and the pathogenesis and progres-
sion of chronic kidney disease [11]. The microvascular
endothelium, by the release of endothelium-derived factors
such as nitric oxide (NO) and as a critical component of the
glomerular ﬁltration barrier, exerts important protection
against progressive renal damage. Endothelial dysfunction
results in increased permeability causing passage of
macromolecules (microalbuminuria), which is considered
to be the earliest renal sign of vascular dysfunction
[14, 15]. Endothelial dysfunction has been shown to predict2 PPAR Research
susceptibility to renal damage in a rat renal injury model
[16].
Progression of renal disease does not only depend
on the degree of microvascular endothelial injury, but
also on the eﬀectiveness of endothelial repair. Impaired
glomerular capillary repair was found to be associated with
the development of glomerulosclerosis and renal failure
[17]. During experimental glomerulonephritis, angiogenic
factors such as VEGF and bFGF are released, which
stimulate endothelial regeneration [18–20]. Blocking the
VEGF-induced endothelial repair with a VEGF-antagonist
interferes with renal recovery and results in progressive renal
impairment [21]. Consistently, progressive renal disease is
associated with reduced expression of angiogenic growth
factors and enhanced expression of antiangiogenic factors
[22, 23]. The glomerular endothelium can recover from
injury by replacing lost or damaged endothelial cells, in part
throughproliferationoflocalendothelium,stimulatedbythe
releaseofangiogenicgrowthfactors[11,12].We[24–26]and
others [27] have observed in both human and experimental
animal studies that damaged glomerular endothelium may
also be regenerated from circulating bone marrow-derived
endothelial progenitor cells. Endothelial progenitor cells
incorporate into the damaged glomerulus, diﬀerentiate into
mature endothelial cells, and eventually fully integrate into
the resident endothelium [26].
Enhancing renal endothelial repair oﬀers therapeutic
potential. Stimulating angiogenesis with VEGF-treatment
augments capillary repair and renal recovery after glomeru-
lonephritis [19]. Enhancing NO production by supplement-
ing the substrate L-arginine improves the clinical course
of anti-Thy-1-glomerulonephritis [28]. Infusion of unse-
lected bone marrow cells ameliorates experimental progres-
sive glomerulosclerosis [29]. Intrarenal administration of
endothelial progenitor cellsattenuatesendothelial injury and
mesangial activation in experimental glomerulonephritis
[30].
3. THE ROLE OF PPAR-γ-RECEPTORS IN
VASCULAR DEVELOPMENT AND REMODELING
Phenotypical studies in humans and animals with genetic
mutations in the PPAR-γ-receptor imply a role in the regu-
lation of vascular function and remodeling. In humans with
dominant-negative heterozygous mutations in the PPAR-γ-
receptor causing an impaired capacity for transcriptional
activation, diabetes and also hypertension occur at an
unusually young age [31]. Heterozygous knockout mice have
increased insulin sensitivity [32] and decreased fat mass
[33], but do not have a vascular phenotype [34]. However,
but PPAR-γ-null mice are embryonically lethal due to
placental dysfunction, characterized by defective trophoblast
diﬀerentiation and markedly impaired placental vascular-
ization [34]. A surviving PPAR-γ-knockout mouse that
was supplemented with a wild-type placenta developed an
apparently normal vascular system during further embryo-
genesis, but died some days after birth due to a combination
of pathologies, including severe lipodystrophic changes
and hemorrhages [34]. In a conditional knockout model
using a cre-lox system to save ﬂoxed PPAR-γ-knockout
mice from embryonic lethality by preserving PPAR-γ-
function in the trophoblast marked lipodystrophy was also
observed,togetherwithinsulinresistance.Surprisingly,these
mice were hypotensive and showed increased endothelium-
dependentrelaxationinresponsetoacetylcholine[35].Inthe
latter study, PPAR-γ-function was deﬁcient in all cell types.
Mice in which PPAR-γ-function was selectively knocked
out in endothelial cells only using again a cre-lox system
were found to be hypertensive when fed a high-fat diet
[36]. Also, in mice with a nonlethal-dominant negative
mutation in the PPAR-γ-receptor, endothelium-dependent
blood vessel dilatation is impaired, while the endothelium
is more sensitive to endothelin-1-induced vasoconstriction
[37]. Superoxide levels in these mice are elevated and
treatment with a superoxide scavenger can reverse the
impaired endothelial vasodilation, highlighting the pivotal
role of increased radical formation [37]. Cerebral arterioles
were hypertrophied with a decrease in luminal diameters,
indicative of adverse inward vascular remodeling [37]. Of
note, dominant negative PPAR-γ-mutations were found not
to be fully selective, therefore, it cannot be excluded that
some of the eﬀects observed in the knockout systems are
attributable to PPAR-γ-receptor-independent signaling, in
particular through the alternative PPAR-receptors [38].
4. EFFECTS OF PPAR-γ-ACTIVATION ON
ENDOTHELIAL PROLIFERATION, MIGRATION,
ANGIOGENESIS, AND APOPTOSIS
Reports on the direct eﬀects of PPAR-γ-agonist treatment on
proliferation, migration, and angiogenic network formation
of cultured endothelial cells showed variable results. Fuku-
naga et al. demonstrated increased proliferation with both
troglitazone and pioglitazone in four diﬀerent endothelial
cell lines [39]. In contrast, two other studies found trogli-
tazone to inhibit proliferation of macrovascular endothelial
cells [40] and human umbilical vein endothelial cells [41].
Rosiglitazone was shown also to inhibit proliferation in one
study [42], while another study found no eﬀect at all [40].
VEGF-induced endothelial migration was found to be
inhibited by PPAR-γ-agonists troglitazone and ciglitazone,
which was mediated by inhibition of Akt [43]. This is in
line with the reduced migration and inhibition of angiogenic
networkformationbyPPAR-γ-agonismobservedbyXinetal
[44]. However, in the study by Fukunaga et al., troglitazone
stimulated both endothelial cell migration and proliferation,
resulting in accelerated coverage of a disrupted endothelial
monolayer in a wound healing assay [39]. Also, Biscetti et
al. found stimulation of endothelial network formation with
PPAR-γ activation using the GW1929 compound, mainly
through a VEGF-dependent mechanism [45].
In vitro eﬀects of PPAR-γ-agonism on endothelial cell
apoptosis have been similarly variable. Both spontaneous
and TNF-alpha-induced endothelial apoptosis were shown
tobeinhibitedbyvariousthiazolidinedionePPAR-γ-agonists
[46] and troglitazone was found to markedly reduce
apoptosis in serum-starved endothelial cells [47], while
another study observed induction of apoptosis using bothP. E. Westerweel and M. C. Verhaar 3
ciglitazone and PPAR-γ-receptor overexpression [48]. In
several studies, the endogenous PPAR-γ ligand 15-deoxy-
delta12,14-prostaglandinJ2(15d-PGJ2)-inducedendothelial
cell apoptosis [46, 48, 49], but it is important to note that
in vascular endothelial cells, the eﬀects of 15d-PGJ2 may be
independent of PPAR-γ-receptor activation [49, 50].
Taken together, it is clear that PPAR-γ-agonists may
modulate endothelial proliferation, migration, angiogenesis,
and apoptosis in vitro, but that this may result in both stim-
ulation and inhibition. The factors that determine whether
treatment with a PPAR-γ-agonist results in a stimulatory or
inhibitory eﬀect on endothelial cells remain largely unidenti-
ﬁed. This may involve PPAR-γ-receptor-independent eﬀects
as reported for 15d-PGJ2 [49, 50] and also with the various
TZDs [45]. Fukunaga et al. posed that a concentration
dependencymayexplain someofthe observeddiscrepancies,
as they observed stimulation of DNA-synthesis at low PPAR-
γ-agonist dosages and inhibition at higher dosages [39].
However, this cannot explain all of the divergent ﬁndings.
In vivo studies in diabetic animals with impaired
angiogenesis in response to peripheral ischemia showed
that treatmentwith PPAR-γ-agonist pioglitazone augmented
the angiogenic response and increased blood ﬂow recovery
[51]. In rats with experimental focal cerebral ischemia,
PPAR-γ-agonist treatment stimulated local angiogenesis and
improved functional neurological recovery [52]. In contrast,
PPAR-γ-agonist treatment inhibited pathological choroidial
and retinal neovascularization [53] and suppressed tumor
growth and metastasis by inhibiting tumor angiogenesis in
several primary tumors, in part through decreasing VEGF-
production by tumor cells and blocking the production
of angiogenic ELR+CXC-chemokines, mediated through
antagonizing NF-kappaB activation [54, 55]. These ﬁndings
suggest that PPAR-γ-agonism may diﬀerentially aﬀect neo-
vascularization with inhibition of pathological neovascular-
ization and augmentation of physiological neovasculariza-
tion. This is in line with the in vitro observations of both
stimulatory and inhibitory actions.
5. EFFECTS OF PPAR-γ-ACTIVATION ON
ENDOTHELIAL DYSFUNCTION
Endothelial integrity does not only rely on the number of
cells, but also on their function. NO-production is a key
component of endothelial function. NO stimulates vasodi-
lation, inhibits inﬂammation, prevents platelet activation,
and scavenges radicals [56]. In vitro studies on the eﬀect
of PPAR-γ-activation have consistently shown a stimulating
eﬀect on NO production by endothelial cells [57–60]. The
observation that siRNA against PPAR-γ blocked the increase
in NO-production conﬁrmed that this eﬀect is PPAR-γ-
receptor mediated [59]. In both experimental animal studies
and in humans, PPAR-γ-activation has been shown to
augment systemic NO-production and endothelial function.
Indiabeticrats,PPAR-γ-agonisttreatmentrestoredimpaired
endothelium-dependent arterial relaxation by increasing
NO-production while reducing oxidative stress [61]. In
healthy human subjects, a single dose of troglitazone
increased NO-dependent endothelial function measured by
venousocclusionplethysmographyoftheforearmandnitrite
levels [62]. In nondiabetic patients with hypertension or
hypercholesterolemia, endothelial function was improved
with pioglitazone [63]. In type 2 diabetic patients, vascular
resistance was shown to be reduced with troglitazone
treatment[64,65]andintype2diabeticpatientswithangina
pectoris, troglitazone reduced the frequency of angina pec-
toriswithimprovingendothelialfunction[66].Rosiglitazone
attenuated the detrimental eﬀects of the presence of diabetes
on NO-production measured directly using an intravital
probe and by assessing blood ﬂow in the peripheral skin
[67]. Long-term treatment with pioglitazone resulted in a
reduced pulse wave velocity, indicative of reduced vascular
stiﬀness [68]. In renal transplant recipients, PPAR-γ-agonist
treatment enhanced endothelial function [69].
Importantly, the observed beneﬁcial eﬀects on systemic
endothelial function were found to extend to improv-
ing intrarenal NO-production. In human type 2 diabetic
patients, rosiglitazone treatment increased intrarenal NO
levels, which was associated with improvement of renal
hemodynamics and reduction of proteinuria [70]. This is
in line with animal studies. In obese Zucker rats, PPAR-γ-
agonist treatment lowered blood pressure and ameliorated
abnormal pressure natriuresis in association with increased
renal NO-metabolite nitrite/nitrate production [71]. In
obese hypertensive Sprague-Dawley rats, PPAR-γ-agonist
treatment also reduced blood pressure, increased NO-
metabolite nitrite/nitrate excretion, and reduced excretion
of oxidative-stress associated urinary isoprostanes and lipid
peroxides [72]. In the kidneys of these rats, eNOS expression
wasincreasedwhilethepathologicalincreaseinp47phoxand
gp91phox associated with obesity was attenuated [72].
Diﬀerences have been observed between the various
PPAR-γ-activating compounds in the signaling level at
which NO-production is stimulated. The NO producing
enzyme endothelial nitric oxide synthase (eNOS) is not only
regulated at the level of transcription and translation, but
also has multiple phosphorylation sites for activation and
deactivation of the enzyme and requires translocation to
the caveolae to associate with its cofactors and eﬀectively
produce NO [73, 74]. Troglitazone has been shown to
enhance NO-production by increasing eNOS transcription
and eNOS protein translation in isolated endothelial cells
[58],whilenoeﬀectwasfoundatthetranscriptional levelfor
15d-PGJ2 [57, 58], pioglitazone [58], and ciglitazone [57].
15d-PGJ2 and rosiglitazone, but not ciglitazone, were found
to stimulate eNOS-phophorylation at activation site ser-
1177, thought to be mediated through increasing heat shock
protein (hsp)-90 association with eNOS [59]. Interestingly,
thereisacross-talkbetweenNOandPPAR-γ pathwaysasNO
has been shown to rapidly and dose-dependently increase
PPAR-γ-binding, mediated by p38 MAPK activation [60].
In vivo, the stimulatory eﬀectofPPAR-γ-agonists rosigli-
tazone and pioglitazone on endothelial NO-production
was associated with increased eNOS-phosphorylation, while
eNOS mRNA and total protein levels were not aﬀected
[51, 75]. Rosiglitazone treatment has been shown to enhance
NO-production through enhancement of cellular transport
of arginine, the substrate for NO [76]. This is particularly4 PPAR Research
relevant for renal disease, as arginine transport was found to
be markedly impaired in uremic conditions [77–79].
PPAR-γ-agonism favorably aﬀects other endothelium-
derived factors that act in conjunction with NO to maintain
endothelial homeostasis. The release of C-type natriuretic
peptide, another vasodilatory peptide, by endothelial cells
is increased by PPAR-γ-agonist treatment [39]. In addi-
tion, PPAR-γ-agonist treatment increased Cu2+ and Zn2+-
superoxide dismutase expression in cultured endothelial
cells, thereby increasing their potential for oxygen radi-
cal scavenging [80, 81]. Also, PPAR-γ-agonist treatment
decreases the production of radical oxygen species in
endothelial cells [81, 82], in part through decreasing the
expression of subunits of NADPH-oxidase [80, 81].
6. ANTIHYPERTENSIVE EFFECTS
OF PPAR-γ-AGONISM MEDIATED BY
THE ENDOTHELIUM
Improving NO-availability is thought to be a major mech-
anism mediating the blood pressure lowering eﬀect of
PPAR-γ-agonisttreatment.Pioglitazonetreatmentprevented
hypertension and renal oxidative stress both by reduc-
ing free-radical production and by increasing nitric oxide
production [72]. No blood pressure reduction was seen
with PPAR-γ-agonist treatment in rats also receiving NO-
inhibitor L-NAME [83]. However, other mechanisms may
play a role in the anti-hypertensive eﬀect of PPAR-γ-
agonist treatment, such as eﬀects on the contractility and
proliferation of smooth muscle cells [84].
A naturally occurring antagonist of NO is the vasocon-
strictor endothelin-1, which is involved in atherosclerosis
and hypertension [85]. PPAR-γ-activation inhibits the pro-
duction of endothelin-1 from endothelial cells in vitro [39,
86–88]. In type 2 diabetic patients, pioglitazone treatment
reduced urinary endothelin-1 secretion, along with decreas-
ing microalbuminuria [89]. Interestingly, in this study,
serum endothelin-1 levels were not aﬀected, suggesting a
speciﬁc pathogenic role for endothelin-1 secretion in the
kidney [89]. In DOCA-salt hypertensive rats, TZD treatment
reducedendothelin-1productionandbluntedradicaloxygen
species production with diminished hypertension progres-
sion and vascular remodeling [90]. Several studies show that
the inhibitory eﬀect of PPAR-γ-activation on endothelin-
1 secretion takes place at the transcriptional level [86, 87]
and it was found to be NO-dependent [87]. Delerive et
al. demonstrated that PPAR-γ-activation negatively inter-
feres with the activator protein-1 signaling cascade, result-
ing in inhibition of thrombin-induced transcription of
endothelin-1 [88].
In hypertension, increased production and secondary
eﬀects of angiotensin-II play a major role. In endothelial
cells, angiotensin-II is a strong inducer of NADPH-oxidase,
resulting in the production of radical oxygen species [91].
Interestingly, there is a cross-talk between the Angiotensin-
II and PPAR-γ signaling pathways. Infusion of angiotensin-
II downregulates PPAR-γ-receptor expression in the vascular
wall [92] and treatment with PPAR-γ-agonists abrogates
many of the angiotensin-II pathophysiological eﬀects [93].
Of note, angiotensin-II-receptor-1 antagonists have been
shown to act as partial PPAR-γ-agonists [94].
7. EFFECTS OF PPAR-γ-ACTIVATION ON
INFLAMMATORY CELL RECRUITMENT TO
THE ENDOTHELIUM
Endothelial cells form an important barrier between the
blood and peripheral tissues and regulate homing, adhe-
sion, and transmigration of inﬂammatory cells. Upon
activation, endothelial cells may further release inﬂamma-
tory cytokines and express adhesion molecules to attract
inﬂammatory cells. PPAR-γ-agonist treatment inhibits the
increased expression of adhesion molecules such as VCAM-
1, ICAM-1, and E-selectin and release of inﬂammatory
cytokines upon stimulation of endothelial cells with PMA
[95, 96], TNF-α [95, 97], IFN-γ [98], IL-1β [99], LPS
[96], microparticles [100], and high glucose [101]. In vitro
studies conﬁrmed that this resulted in decreased adhesion
of inﬂammatory cells to the endothelium [96, 97, 101,
102]. In addition, a recent study showed that in activated
primary human brain endothelial cells, PPAR-γ-activation
resulted in a marked reduction of monocyte adhesion and
in vitro transendothelial migration, mediated by inhibition
of Rac1 and RhoA GTPases [102]. In vivo, troglitazone
and 15d-PGJ2 reduced ICAM-1 and VCAM-1 expression on
endothelial cells and reduced inﬂammatory cell homing to
atherosclerotic plaques in a mouse model [103].
8. EFFECTS OF PPAR-γ-ACTIVATION ON
ENDOTHELIAL PROGENITOR CELLS
A recently uncovered eﬀect of PPAR-γ-agonists is the
capacity to augment the level and function of endothe-
lial progenitor cells. PPAR-γ-agonist treatment increases
endothelial progenitor cell levels in mice [104, 105]a n d
humans [104, 106, 107]. A stimulatory eﬀect on endothelial
progenitor cell outgrowth was also observed when cultured
peripheral blood mononuclear cells were exposed to PPAR-
γ-agonist treatment ex vivo [104, 105, 108, 109], suggesting
an eﬀect on endothelial progenitor cell survival, adhesion, or
diﬀerentiation. PPAR-γ-agonist treatment largely prevented
apoptosis of endothelial progenitor cells induced by CRP
[109]a n dH 2O2 [105]. Based on marker expression patterns,
the diﬀerentiation of endothelial progenitor cells toward the
endotheliallineageappearstobestimulated[104,108],while
expression of smooth muscle cell markers is inhibited [104].
Pioglitazone inhibited detrimental eﬀects of angiotensin-
II on endothelial progenitor cells, including inhibiting the
induction of cellular senescence of endothelial progenitor
cells via downregulation of the expression of angiotensin-II-
receptor-1andlimitingtheangiotensin-II-inducedincreased
generation of peroxynitrate and superoxide by the NADPH-
oxidase subunit gp91phox [110].
Functionally, PPAR-γ-agonist treatment was shown to
stimulate angiogenic network formation by endothelial
progenitor cells in vitro [109] and in vivo [105]. The
adhesion capacity may be increased upon TZD-treatment
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reendothelialization of a denuded segment of the femoral
artery in mice was accelerated in PPAR-γ-agonist treated
animals [104]. As endothelial progenitor cells may also par-
ticipate in regeneration of damaged renal endothelium [26],
we investigated a potential role for enhanced endothelial
progenitor cell homing and glomerular incorporation by
PPAR-γ-agonisttreatment[7].However,usingaratallogenic
bone marrow transplantation model, we could not detect
an eﬀect on the number of incorporated circulation-derived
glomerular endothelial cells in the recovering glomerulus
with rosiglitazone treatment, although rosiglitazone did
attenuate the clinical course of glomerulonephritis.
9. CONCLUSIONSAND PERSPECTIVES
Activation of the PPAR-γ-receptors present on renal
endothelial cells aﬀects their cellular behavior. Proliferation,
apoptosis, migration, and angiogenesis by endothelial cells
are modulated, but may involve both stimulation and inhi-
bition depending on the speciﬁc circumstances. It remains
unclear how this bimodal potential of PPAR-γ-agonists is
regulated. An important consequence of PPAR-γ-receptor
activation is the enhanced production of nitric oxide and
C-type natriuretic peptide and superoxide dismutase, while
endothelin-1productionisinhibited.Together,thisimproves
the capacity of the endothelium to exert vasodilatory,
anti-inﬂammatory, and antioxidative actions, resulting in
blood pressure lowering and direct renoprotective eﬀects.
In addition, the presentation of adhesion molecules and
release of cytokines aimed at recruiting inﬂammatory cells to
activated endothelium is inhibited by PPAR-γ-agonism. This
may also in part account for the anti-inﬂammatory eﬀects
of PPAR-γ-agonists, supplementary to direct eﬀects on the
inﬂammatory cells themselves. Finally, PPAR-γ-receptors
are also found on endothelial progenitor cells and PPAR-
γ-agonist stimulate progenitor-mediated endothelial repair,
although deﬁnitive evidence that this occurs in the kidney is
currently lacking.
Activation of other PPAR-receptors besides PPAR-γ may
also have beneﬁcial eﬀects on the endothelium. Recently,
selective agonists for PPAR-β/δ were developed [111]. PPAR-
β/δ receptors are present on endothelium and stimulation
with a pharmacological PPAR-β/δ-agonist was found to
increase endothelial cell proliferation and angiogenesis in
vitro and in vivo, mainly mediated through VEGF [112].
Like PPAR-γ-agonists, PPAR-β/δ-agonists increase circulat-
ing endothelial progenitor cell levels, augment endothelial
progenitor cell function in vitro, and improve endothelial
progenitor cell-mediated neovascularization of ischemic
tissue [113]. Also, much like PPAR-γ-agonists, PPAR-
β/δ-agonist treatment reduced the expression of adhesion
molecules and monocyte binding to activated endothelial
cells [114].
Currently, PPAR-γ-agonist treatment is not standard
clinical practice in nondiabetic renal patients. As shown in
this review, experimental studies indicate that stimulatory
eﬀects of PPAR-γ-agonism on endothelium may provide
additional beneﬁt in nondiabetic renal disease. Together
with other potentially therapeutic eﬀects independent of
the insulin-sensitizing action such as the anti-inﬂammatory
actions, this provides a rationale for further clinical evalua-
tion in nondiabetic renal patients. For patients with diabetic
kidney disease, a pressing question is whether glycemic
control with a TZD is superior to other antidiabetic drugs
for preventing the decline of renal function. To date, only
retrospective studies, post hoc analyses, and pilot studies
are available to help answer this question. Trials designed to
speciﬁcally evaluate this question have yet to be performed.
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